{"id":11088,"date":"2018-08-01T10:31:47","date_gmt":"2018-08-01T14:31:47","guid":{"rendered":"https:\/\/medicarereport.org\/?p=11088"},"modified":"2018-08-01T10:31:47","modified_gmt":"2018-08-01T14:31:47","slug":"pfizer-ceo-predicts-that-controversial-rebates-are-going-away","status":"publish","type":"post","link":"https:\/\/medicarereport.org\/?p=11088","title":{"rendered":"Pfizer CEO predicts that controversial rebates are \u2018going away\u2019"},"content":{"rendered":"<p>(By Ed Silverman for ST<em>A<\/em>T)<\/p>\n<p class=\"big-cap-wrap danger-zone\"><span class=\"big-cap\">In his first public remarks since rescinding price hikes, Pfizer chief executive officer Ian Read predicted the controversial rebates that drug makers pay to pharmacy benefit managers will soon disappear.<a href=\"https:\/\/www.statnews.com\/pharmalot\/2018\/07\/31\/pfizer-read-trump-rebates\/?utm_campaign=KHN%3A%20Daily%20Health%20Policy%20Report&amp;utm_source=hs_email&amp;utm_medium=email&amp;utm_content=64888976&amp;_hsenc=p2ANqtz-86bug5B89Zkkb3OgHCnwt-XLEwKX3rECZ6eeV7rHL3ZqGjQ5YvmavVeHojWHIfLvHVAxEFs0aXxk6WhsNzLQGeGlRQAw&amp;_hsmi=64888976\"> Continue reading article here&#8230;<\/a><\/span><\/p>\n<p class=\"big-cap-wrap danger-zone\"><a href=\"https:\/\/medicarereport.org\/wp-content\/uploads\/2016\/09\/STAT-Logo.png\"><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-4372\" src=\"https:\/\/medicarereport.org\/wp-content\/uploads\/2016\/09\/STAT-Logo-300x32.png\" alt=\"\" width=\"300\" height=\"32\" srcset=\"https:\/\/medicarereport.org\/wp-content\/uploads\/2016\/09\/STAT-Logo-300x32.png 300w, https:\/\/medicarereport.org\/wp-content\/uploads\/2016\/09\/STAT-Logo.png 453w\" sizes=\"auto, (max-width: 300px) 100vw, 300px\" \/><\/a><\/p>\n<p class=\"big-cap-wrap danger-zone\">\n<pre>Notice: The link provided above connects readers to the full content of the posted article. The URL (internet address) for this link is valid on the posted date; medicarereport.org cannot guarantee the duration of the link\u2019s validity. Also, the opinions expressed in these postings are the viewpoints of the original source and are not explicitly endorsed by AMAC, Inc.; the AMAC Foundation, Inc.; or medicarereport.org.<\/pre>\n","protected":false},"excerpt":{"rendered":"<p>(By Ed Silverman for STAT) In his first public remarks since rescinding price hikes, Pfizer chief executive officer Ian Read<\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[21,15],"tags":[],"class_list":["post-11088","post","type-post","status-publish","format-standard","hentry","category-health-care-finance","category-part-dprescription-drugs"],"_links":{"self":[{"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/posts\/11088","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/medicarereport.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=11088"}],"version-history":[{"count":1,"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/posts\/11088\/revisions"}],"predecessor-version":[{"id":11089,"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/posts\/11088\/revisions\/11089"}],"wp:attachment":[{"href":"https:\/\/medicarereport.org\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=11088"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/medicarereport.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=11088"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/medicarereport.org\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=11088"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}